Incretin ReviewResearch · Context · Care

The reading room

Evidence notes and provider dossiers

Read the denominator, the study design and the limits of the claim.

01Provider dossier

Best GLP-1 providers: what the evidence can tell you

A ten-option starting list, with the boundary between an advertised service and demonstrated outcomes made explicit.

Read the note ↗
02Evidence note 01

A 20% lower hazard is not a 20-point difference

Reading the SELECT cardiovascular trial without confusing a relative measure, an observed proportion and a personal forecast.

Read the note ↗
03Evidence note 02

Why a safety-report count is not an event rate

Reports can reveal important signals without providing a denominator, a causal verdict or a fair ranking of medicines.

Read the note ↗
04Evidence note 03

When a study result becomes a marketing claim

Follow the chain from the original research to the product, population and service being advertised.

Read the note ↗
05Evidence methods

A composite endpoint contains more than one outcome

Before repeating a cardiovascular claim, identify what counted as an event and how the result was measured.

Read the note ↗
06Research appraisal

Read the funding statement, then keep reading the methods

Sponsorship is relevant context. It does not replace examination of the study question, design and reporting.

Read the note ↗
07Reading boundaries

What you can responsibly take from a trial abstract

An abstract can orient a reader while leaving important methods and results outside the available view.

Read the note ↗
08Scientific article

ESSENCE and MASH: Reading the Biopsy Evidence Before Long-Term Outcomes

The 72-week ESSENCE analysis found meaningful biopsy improvements with weekly injectable semaglutide. Its accelerated MASH approval rests on those findings, while longer follow-up addresses liver complications and survival.

Read the note ↗
09Scientific article

Oral Orforglipron in ATTAIN-1: Weight Results, Safety, and Formulation

The 72-week trial established a weight-loss benefit over placebo. Interpreting that benefit requires separating study doses from marketed tablets, averages from individual responses, and clinical evidence from care-plan claims.

Read the note ↗